BIOVENTUS INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$158M
↑+2.8% +$4Mvs FY2024 (Q4)
Gross Profit
$109M
↑+6.0% +$6Mvs FY2024 (Q4)
Operating Income
$19M
Net Income
$14M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $158M | $154M |
| COGS | $49M | $51M |
| Gross Profit | $109M | $103M |
| R&D | $3M | $3M |
| SG&A | $83M | $87M |
| D&A | $4M | $12M |
| Other OpEx | $0 | $107K |
| Operating Income | $19M | $0 |
| Interest Exp. | $5M | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $14M | $0 |
| Tax | $0 | $0 |
| Net Income | $14M | $0 |
QuarterCharts · SEC EDGAR data · BVS · Comparing FY2025 (Q4) vs FY2024 (Q4)